NFKB1 and primary cutaneous T-cell non-Hodgkin lymphoma: NF-κB has been shown as an essential downstream target of DMF in breast cancer, glioblastoma and cutaneous T-cell lymphoma (CTCL) (Ghods et al., 2013; Tavallai et al., 2016; Bennett Saidu et al., 2018).